NCT01578720View on ClinicalTrials.gov

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

March 31, 2015

Conditions
Choroidal NeovascularizationPresumed Ocular Histoplasmosis
Interventions
DRUG

EYLEA (Aflibercept) intravitreal injection

Intravitreal Injection once every 8 weeks with 3 initial monthly doses

Trial Locations (3)

63017

The Retina Institute, St Louis

63128

The Retina Institute, St Louis

63144

The Retina Institute, St Louis

All Listed Sponsors
lead

Retina Research Institute, LLC

OTHER

NCT01578720 - Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome | Biotech Hunter | Biotech Hunter